CSPC Pharma awards 1.35 million restricted shares to two employees under 2018 scheme

Bulletin Express06-08 20:03

CSPC Pharmaceutical Group Limited (CSPC Pharma) disclosed that on 8 June 2026 it granted 1.35 million restricted shares to two selected participants at nil consideration pursuant to its 2018 Share Award Scheme.

The award equals about 0.01% of the company’s issued share capital. Shares will vest in two tranches: 1.10 million on 23 January 2027 and 0.25 million on 23 January 2028, contingent on the employees meeting individual annual performance targets. A clawback mechanism allows all unvested shares to lapse if the grantee leaves the group for misconduct, is convicted of integrity-related offences, or breaches securities regulations.

Consistent with amendments approved on 21 May 2024, the scheme is funded solely by existing shares purchased on-market; no new shares will be issued for this grant. Following the transaction, 60.21 million shares remain available for future awards under the plan, compared with the original 124.86 million cap (not more than 2% of issued share capital at adoption).

The grant complies with Hong Kong Listing Rule 17.12 governing share schemes funded by existing shares. None of the grantees is a director, chief executive, substantial shareholder or an associate of any of them.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135559233?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-08 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135559233","market":"hk","top_or_hot":-1,"title":"CSPC Pharma awards 1.35 million restricted shares to two employees under 2018 scheme","media":"Bulletin Express","content":"<p>CSPC Pharmaceutical Group Limited (CSPC Pharma) disclosed that on 8 June 2026 it granted 1.35 million restricted shares to two selected participants at nil consideration pursuant to its 2018 Share Award Scheme.</p>\n<p>The award equals about 0.01% of the company’s issued share capital. Shares will vest in two tranches: 1.10 million on 23 January 2027 and 0.25 million on 23 January 2028, contingent on the employees meeting individual annual performance targets. A clawback mechanism allows all unvested shares to lapse if the grantee leaves the group for misconduct, is convicted of integrity-related offences, or breaches securities regulations.</p>\n<p>Consistent with amendments approved on 21 May 2024, the scheme is funded solely by existing shares purchased on-market; no new shares will be issued for this grant. Following the transaction, 60.21 million shares remain available for future awards under the plan, compared with the original 124.86 million cap (not more than 2% of issued share capital at adoption).</p>\n<p>The grant complies with Hong Kong Listing Rule 17.12 governing share schemes funded by existing shares. None of the grantees is a director, chief executive, substantial shareholder or an associate of any of them.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC Pharma awards 1.35 million restricted shares to two employees under 2018 scheme</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC Pharma awards 1.35 million restricted shares to two employees under 2018 scheme\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-08 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSPC Pharmaceutical Group Limited (CSPC Pharma) disclosed that on 8 June 2026 it granted 1.35 million restricted shares to two selected participants at nil consideration pursuant to its 2018 Share Award Scheme.</p>\n<p>The award equals about 0.01% of the company’s issued share capital. Shares will vest in two tranches: 1.10 million on 23 January 2027 and 0.25 million on 23 January 2028, contingent on the employees meeting individual annual performance targets. A clawback mechanism allows all unvested shares to lapse if the grantee leaves the group for misconduct, is convicted of integrity-related offences, or breaches securities regulations.</p>\n<p>Consistent with amendments approved on 21 May 2024, the scheme is funded solely by existing shares purchased on-market; no new shares will be issued for this grant. Following the transaction, 60.21 million shares remain available for future awards under the plan, compared with the original 124.86 million cap (not more than 2% of issued share capital at adoption).</p>\n<p>The grant complies with Hong Kong Listing Rule 17.12 governing share schemes funded by existing shares. None of the grantees is a director, chief executive, substantial shareholder or an associate of any of them.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1135559233","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135559233","pubTimestamp":1780920218,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CSPC Pharmaceutical Group Limited (CSPC Pharma) disclosed that on 8 June 2026 it granted 1.35 million restricted shares to two selected participants at nil consideration pursuant to its 2018 Share...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"石药集团根据2018年计划向两名员工授予135万股限制性股票","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"CSPC Pharmaceutical Group Limited (CSPC Pharma) disclosed that on 8 June 2026 it granted 1.35 million restricted shares to two selected participants at nil consideration pursuant to its 2018 Share Award Scheme.\nThe award equals about 0.01% of the company’s issued share capital. Shares will vest in two tranches: 1.10 million on 23 January 2027 and 0.25 million on 23 January 2028, contingent on the employees meeting individual annual performance targets. A clawback mechanism allows all unvested shares to lapse if the grantee leaves the group for misconduct, is convicted of integrity-related offences, or breaches securities regulations.\nConsistent with amendments approved on 21 May 2024, the scheme is funded solely by existing shares purchased on-market; no new shares will be issued for this grant. Following the transaction, 60.21 million shares remain available for future awards under the plan, compared with the original 124.86 million cap (not more than 2% of issued share capital at adoption).\nThe grant complies with Hong Kong Listing Rule 17.12 governing share schemes funded by existing shares. None of the grantees is a director, chief executive, substantial shareholder or an associate of any of them.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135559233","isCrawlerRequest":true}